The Canadian contract development and manufacturing organisation (CDMO) completed work on its new biologics manufacturing wing at its facility in Toronto just this week – adding three new bioreactors, 200 meters of cleanroom space and purification and fill finish capabilities to its offering.
Spokeswoman Dina Iezzi told Outsourcing-pharma.com that the decision join the biologics contractor sector was based on the potential the firm sees in the market.
“Therapeutic biologics are a rapidly expanding market representing roughly 50 per cent of all NDA submissions to the FDA. According to Business Monitor International (BMI), the global biologic CDMO market is forecasted to grow from $22.2bn in 2009 to $33.7bn by 2014.”
She also set the move in the context of Therapure’s wider business, explaining that the firm can now offer “CDMO services including biologic API manufacturing as well as aseptic fill/finish and analytical testing services for both large and small molecules.”
Therapure is not the only firm to have joined biologics contracting sector of late – in March last year for example Quintiles teamed up with Samsung to establish a manufacturing JV and since then Fujifilm and Catalent each adding their own production capacity.
However, such competition is not to be a major concern for Therapure according to Iezzi who suggested that: “Therapure offers clients a number of advantages over the large players in the CDMO market.
“As a company with a long history of product development, Therapure is able to provide clients small and large with insightful advice / solutions to meet their manufacturing needs – from product development to test development to scale-up evaluation and process development and fully integrated services for clinical as well as commercial launch.
She added that: “Therapure has the ability to be more flexible regarding client needs than many of the larger players in the CDMO market.”